Dietary Approaches to Stop Hypertension (DASH) and mortality risk among patients with liver cirrhosis: a prospective cohort study.
Cirrhosis
DASH
Mortality
Survival
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
received:
20
11
2023
accepted:
29
08
2024
medline:
5
9
2024
pubmed:
5
9
2024
entrez:
5
9
2024
Statut:
epublish
Résumé
The relationship between dietary patterns and cirrhosis is undeniable. The present study aimed to investigate the association between the Dietary Approaches to Stop Hypertension (DASH) diet and the risk of mortality in patients with cirrhosis prospectively. In this cohort study, 121 cirrhotic patients were enrolled and followed up annually for four years. Nutritional status and dietary intakes were assessed initially, and the DASH score was calculated accordingly. Crude and multivariable-adjusted hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox proportional hazard analyses. DASH components including fruits, vegetables, legumes, nuts and seeds, and low-fat dairy products were significantly associated with lower mortality risk in cirrhotic patients. Also, a higher DASH score was significantly associated with a reduction in the risk of mortality in patients with cirrhosis, so that after adjusting for all confounders, the risk of mortality in the upper tertile was 89% lower than the first tertile (HR = 0.11, 95% CI: 0.03-0.42, P trend < 0.001). The 4-year survival rate among patients across tertiles of DASH was 32%, 37%, and 46%, respectively (P = 0.005). It can be concluded that a higher DASH diet score may be associated with a reduced risk of mortality in cirrhotic patients. However, larger studies are needed to confirm the findings and determine their potential mechanisms.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
The relationship between dietary patterns and cirrhosis is undeniable. The present study aimed to investigate the association between the Dietary Approaches to Stop Hypertension (DASH) diet and the risk of mortality in patients with cirrhosis prospectively.
METHODS
METHODS
In this cohort study, 121 cirrhotic patients were enrolled and followed up annually for four years. Nutritional status and dietary intakes were assessed initially, and the DASH score was calculated accordingly. Crude and multivariable-adjusted hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox proportional hazard analyses.
RESULTS
RESULTS
DASH components including fruits, vegetables, legumes, nuts and seeds, and low-fat dairy products were significantly associated with lower mortality risk in cirrhotic patients. Also, a higher DASH score was significantly associated with a reduction in the risk of mortality in patients with cirrhosis, so that after adjusting for all confounders, the risk of mortality in the upper tertile was 89% lower than the first tertile (HR = 0.11, 95% CI: 0.03-0.42, P trend < 0.001). The 4-year survival rate among patients across tertiles of DASH was 32%, 37%, and 46%, respectively (P = 0.005).
CONCLUSION
CONCLUSIONS
It can be concluded that a higher DASH diet score may be associated with a reduced risk of mortality in cirrhotic patients. However, larger studies are needed to confirm the findings and determine their potential mechanisms.
Identifiants
pubmed: 39232774
doi: 10.1186/s13104-024-06928-z
pii: 10.1186/s13104-024-06928-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
248Informations de copyright
© 2024. The Author(s).
Références
Yao CK, Fung J, Chu NHS, Tan VPY. Dietary interventions in liver cirrhosis. J Clin Gastroenterol. 2018;52(8):663–73.
doi: 10.1097/MCG.0000000000001071
pubmed: 29912757
Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398(10308):1359–76.
doi: 10.1016/S0140-6736(21)01374-X
pubmed: 34543610
Pashayee-khamene F, Hatami B, Cheraghpour M, Yari Z. Keeping an eye on the nutrition: the importance of nutrition management on cardiometabolic risk factors in cirrhotic patients. Clin Nutr ESPEN. 2023.
GinËs P, Krag A, Abraldes J, Sol‡ E, Fabrellas N, Kamath PS. Liver Cirrhosis Lancet. 2021;398(10308):1359–76.
pubmed: 34543610
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–71.
doi: 10.1016/j.jhep.2018.09.014
pubmed: 30266282
Bataller R, Brenner DA. Liver fibrosis. J Clin Investig. 2005;115(2):209–18.
doi: 10.1172/JCI24282
pubmed: 15690074
pmcid: 546435
Hydes TJ, Ravi S, Loomba R, M EG. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clin Mol Hepatol. 2020;26(4):383–400.
doi: 10.3350/cmh.2020.0067
pubmed: 32674529
pmcid: 7641567
Wickman BE, Enkhmaa B, Ridberg R, Romero E, Cadeiras M, Meyers F et al. Dietary Management of Heart failure: DASH Diet and Precision Nutrition perspectives. Nutrients. 2021;13(12).
Aleksandrova K, Koelman L, Rodrigues CE. Dietary patterns and biomarkers of oxidative stress and inflammation: a systematic review of observational and intervention studies. Redox Biol. 2021;42:101869.
doi: 10.1016/j.redox.2021.101869
pubmed: 33541846
pmcid: 8113044
Juraschek SP, Kovell LC, Appel LJ, Miller ER 3rd, Sacks FM, Chang AR, et al. Effects of Diet and Sodium reduction on Cardiac Injury, strain, and inflammation: the DASH-Sodium trial. J Am Coll Cardiol. 2021;77(21):2625–34.
Pirouzeh R, Heidarzadeh-Esfahani N, Morvaridzadeh M, Izadi A, Yosaee S, Potter E, et al. Effect of DASH diet on oxidative stress parameters: a systematic review and meta-analysis of randomized clinical trials. Diabetes Metabolic Syndrome. 2020;14(6):2131–8.
doi: 10.1016/j.dsx.2020.10.031
pubmed: 33395773
Hinderliter AL, Babyak MA, Sherwood A, Blumenthal JA. The DASH diet and insulin sensitivity. Curr Hypertens Rep. 2011;13(1):67–73.
doi: 10.1007/s11906-010-0168-5
pubmed: 21058045
pmcid: 3767170
Kucharska A, Gajewska D, Kiedrowski M, Sińska B, Juszczyk G, Czerw A, et al. The impact of individualised nutritional therapy according to DASH diet on blood pressure, body mass, and selected biochemical parameters in overweight/obese patients with primary arterial hypertension: a prospective randomised study. Kardiologia Polska. 2018;76(1):158–65.
doi: 10.5603/KP.a2017.0184
pubmed: 28980293
Chiavaroli L, Viguiliouk E, Nishi SK, Blanco Mejia S, Rahelić D, Kahleová H et al. DASH Dietary Pattern and Cardiometabolic outcomes: an Umbrella Review of systematic reviews and Meta-analyses. Nutrients. 2019;11(2).
Asghari G, Rezazadeh A, Hosseini-Esfahani F, Mehrabi Y, Mirmiran P, Azizi F. Reliability, comparative validity and stability of dietary patterns derived from an FFQ in the Tehran lipid and glucose study. Br J Nutr. 2012;108(6):1109–17.
doi: 10.1017/S0007114511006313
pubmed: 22251608
Fung TT, Chiuve SE, McCullough ML, Rexrode KM, Logroscino G, Hu FB. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med. 2008;168(7):713–20.
doi: 10.1001/archinte.168.7.713
pubmed: 18413553
Mirmiran P, Hosseini Esfahani F, Mehrabi Y, Hedayati M, Azizi F. Reliability and relative validity of an FFQ for nutrients in the Tehran lipid and glucose study. Public Health Nutr. 2009;13(5):654–62.
doi: 10.1017/S1368980009991698
pubmed: 19807937
Razavi Zade M, Telkabadi MH, Bahmani F, Salehi B, Farshbaf S, Asemi Z. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial. Liver Int. 2016;36(4):563–71.
doi: 10.1111/liv.12990
pubmed: 26503843
Xiao M-L, Lin J-S, Li Y-H, Liu M, Deng Y-Y, Wang C-Y, et al. Adherence to the Dietary approaches to stop hypertension (DASH) diet is associated with lower presence of non-alcoholic fatty liver disease in middle-aged and elderly adults. Public Health Nutr. 2020;23(4):674–82.
doi: 10.1017/S1368980019002568
pubmed: 31566148
Mahdavi A, Mohammadi H, Bagherniya M, Foshati S, Clark CC, Moafi A, et al. The effect of the Dietary approaches to stop hypertension (DASH) diet on body composition, complete blood count, prothrombin time, inflammation and liver function in haemophilic adolescents. Br J Nutr. 2022;128(9):1771–9.
doi: 10.1017/S0007114521004839
pubmed: 34863320
Rooholahzadegan F, Arefhosseini S, Tutunchi H, Badali T, Khoshbaten M, Ebrahimi-Mameghani M. The effect of DASH diet on glycemic response, meta-inflammation and serum LPS in obese patients with NAFLD: a double-blind controlled randomized clinical trial. Nutr Metabolism. 2023;20(1):11.
doi: 10.1186/s12986-023-00733-4
Park SY, Noureddin M, Boushey C, Wilkens LR, Setiawan VW. Diet Quality Association with nonalcoholic fatty liver disease by cirrhosis status: the multiethnic cohort. Curr Developments Nutr. 2020;4(3):nzaa024.
doi: 10.1093/cdn/nzaa024
Stephenson K, Kennedy L, Hargrove L, Demieville J, Thomson J, Alpini G, et al. Updates on Dietary models of nonalcoholic fatty liver disease: current studies and insights. Gene Expr. 2018;18(1):5–17.
doi: 10.3727/105221617X15093707969658
pubmed: 29096730
pmcid: 5860971
Razavi Zade M, Telkabadi MH, Bahmani F, Salehi B, Farshbaf S, Asemi Z. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial. Liver International: Official J Int Association Study Liver. 2016;36(4):563–71.
doi: 10.1111/liv.12990
Cao Y, Wang C, Liu J, Liu ZM, Ling WH, Chen YM. Greater serum carotenoid levels associated with lower prevalence of nonalcoholic fatty liver disease in Chinese adults. Sci Rep. 2015;5:12951.
doi: 10.1038/srep12951
pubmed: 26256414
pmcid: 4530335
Yilmaz B, Sahin K, Bilen H, Bahcecioglu IH, Bilir B, Ashraf S, et al. Carotenoids and non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2015;4(3):161–71.
pubmed: 26151056
pmcid: 4465602
Hekmatdoost A, Shamsipour A, Meibodi M, Gheibizadeh N, Eslamparast T, Poustchi H. Adherence to the Dietary approaches to stop hypertension (DASH) and risk of nonalcoholic fatty liver disease. Int J Food Sci Nutr. 2016;67(8):1024–9.
doi: 10.1080/09637486.2016.1210101
pubmed: 27436528
Chan W-K, Chuah K-H, Rajaram RB, Lim L-L, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metabolic Syndrome. 2023;32(3):197.
doi: 10.7570/jomes23052
Paik JM, Mir S, Alqahtani SA, Younossi Y, Ong JP, Younossi ZM. Dietary risks for liver mortality in NAFLD: global burden of disease data. Hepatol Commun. 2022;6(1):90–100.
doi: 10.1002/hep4.1707
pubmed: 34558838
Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F. Cardiovascular dysfunction in patients with liver cirrhosis. Annals Gastroenterology: Q Publication Hellenic Soc Gastroenterol. 2015;28(1):31.
Cesari M, Frigo AC, Tonon M, Angeli P. Cardiovascular predictors of death in patients with cirrhosis. Hepatology. 2018;68(1):215–23.
doi: 10.1002/hep.29520
pubmed: 28902431
Sotos-Prieto M, Bhupathiraju SN, Mattei J, Fung TT, Li Y, Pan A, et al. Changes in Diet Quality scores and Risk of Cardiovascular Disease among US men and women. Circulation. 2015;132(23):2212–9.
doi: 10.1161/CIRCULATIONAHA.115.017158
pubmed: 26644246
pmcid: 4673892
Jeong SY, Wee CC, Kovell LC, Plante TB, Miller ER 3rd, Appel LJ, et al. Effects of Diet on 10-Year atherosclerotic Cardiovascular Disease Risk (from the DASH Trial). Am J Cardiol. 2023;187:10–7.
Shoaibinobarian N, Danehchin L, Mozafarinia M, Hekmatdoost A, Eghtesad S, Masoudi S, et al. The Association between DASH Diet Adherence and Cardiovascular Risk factors. Int J Prev Med. 2023;14:24.
doi: 10.4103/ijpvm.ijpvm_336_21
pubmed: 37033286
pmcid: 10080575
Bonekamp NE, Cruijsen E, Visseren FL, van der Schouw YT, Geleijnse JM, Koopal C. Compliance with the DASH diet and risk of all-cause and cardiovascular mortality in patients with myocardial infarction. Clin Nutr. 2023;42(8):1418–26.
doi: 10.1016/j.clnu.2023.06.033
pubmed: 37433229
Siervo M, Lara J, Chowdhury S, Ashor A, Oggioni C, Mathers JC. Effects of the Dietary Approach to stop hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. Br J Nutr. 2015;113(1):1–15.
doi: 10.1017/S0007114514003341
pubmed: 25430608